Skip to Main content Skip to Navigation
Journal articles

Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*

Bello Hamidou 1 Benoît Marin 1 Géraldine Lautrette 2, 3 Marie Nicol 2, 1, 3 William Camu 4, 5, 6 Philippe Corcia 7, 8 Marie-Christine Arnes-Bes 9 Christine Tranchant 10 Pierre Clavelou 11, 12 Didier Hannequin 13 Giroud Maurice 14 Katell Beauvais 15 Jean-Christophe Antoine 16, 17 Véronique Danel-Brunaud 18 Fausto Viader 19 Pierre-Marie Preux 1 Philippe Couratier 2, 1, 3
Abstract : Objectives were: i) to describe the phenotypic heterogeneity of incident amyotrophic lateral sclerosis (ALS) patients diagnosed in 2012 in French ALS centres; ii) to look at the associations between ALSFRS-R score and ALSFRS-R slope (ΔFS) at time of diagnosis with diagnosis delay, ALS phenotypes and Airlie House diagnosis criteria (AHDC); iii) to describe the rate of progression on ΔFS, according to diagnosis delay. METHODS: Incident ALS cases diagnosed in French ALS centres were included. The rate of progression was evaluated as follows: ΔFS = (48 - ALSFRS-R at time of diagnosis)/duration from onset to diagnosis (months). Fast and slow progressors were defined by ΔFS >1 and <0.5, respectively. RESULTS: At time of diagnosis, 476 patients were classified into eight phenotypes: bulbar (33.0%), spinal lumbar (28.2%), spinal cervical (23.1%), flail leg (4.4%), ALS/FTD (4.2%), possible flail arm (4.0%), respiratory (2.1%), dropped-head (1.0%). Median ΔFS (n = 358/476) was 1.0 [0.5-2.0]. ΔFS was associated with AHDC (p = 0.009), but not with clinical phenotype (p = 0.902). Stratification on diagnosis delay (<12 months or ≥18 months) allowed to differentiate fast progressors from slow progressors. CONCLUSION: At time of inclusion in therapeutic trial closed to diagnosis, ΔFS or diagnosis delay may discriminate the rate of progression.
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-01757319
Contributor : Anthony Herrada Connect in order to contact the contributor
Submitted on : Tuesday, April 3, 2018 - 4:09:51 PM
Last modification on : Tuesday, October 19, 2021 - 12:16:08 PM

Identifiers

Citation

Bello Hamidou, Benoît Marin, Géraldine Lautrette, Marie Nicol, William Camu, et al.. Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Taylor & Francis, 2017, 18 (7-8), pp.519 - 527. ⟨10.1080/21678421.2017.1353098⟩. ⟨hal-01757319⟩

Share

Metrics

Record views

248